Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naive patients with advanced non small-cell lung cancer. Antonia, S., Kim, S., Spira, A. I., Ahn, M., Ou, S., Stjepanovic, N., Fasolo, A., Jagert, D., Ottt, P., Wainberg, Z. A., Wakelee, H. A., Goldman, J., Kurland, J., Rebelatto, M. C., Yao, W., Gupta, A., Blake-Haskins, J. A., Segal, N. AMER SOC CLINICAL ONCOLOGY. 2016

View details for DOI 10.1200/JCO.2016.34.15_suppl.9029

View details for Web of Science ID 000404711506177